Long-term follow-up of the KEYNOTE-240* trial showed that improvements in overall survival (OS) and progression-free survival (PFS) with pembrolizumabwere maintained in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, according to updated results of the trial presented at ASCO GI 2021.
In patients with metastatic colorectal cancer (mCRC), the addition of anlotinib to best supportive care did not confer overall survival (OS) benefit, though there was improvement in progression-free survival (PFS), according to results of the phase III ALTER0703 trial presented at ASCO GI 2021.
A combination therapy of S-1 plus docetaxel in the adjuvant setting is not only superior to S-1 alone for recurrence-free survival (RFS) following D2 gastrectomy for stage III gastric cancer, it also confers overall survival (OS) benefit, according to the updated analysis of the JACCRO GC-07 trial presented at ASCO GICS 2021.
Infigratinib may be a suitable second- or later-line treatment option for patients with advanced or metastatic cholangiocarcinoma (CCA) with FGFR2* fusions or rearrangements, according to interim results of a phase II, open-label, single-arm study presented at ASCO GI 2021.
In the final analysis of the phase III ClarIDHy trial, ivosidenib was well-tolerated and had a favourable overall survival (OS) benefit despite a high crossover rate from placebo among individuals with previously treated advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (mIDH1 CCA).
The addition of the human immunoglobulin G1 monoclonal antibody ramucirumab to paclitaxel led to a significant progression-free survival (PFS) benefit in a subgroup of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed standard first-line chemotherapy with platinum and fluoropyrimidine (with or without anthracycline), according to the findings of the RAINBOW-Asia study, a bridging study of the RAINBOW trial, presented at ASCO GI 2021.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.